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Abstract: A low testosterone level contributes to the development of oxidative damages; however,
the cardiovascular effects of exogenous hormone therapy are not well elucidated. The aim of our work
is to study the association of the testosterone level, antioxidant/oxidant system, and anti-inflammatory
status related to the heme oxygenase (HO) system. To determine the effects of testosterone, 10-week-old,
and 24-month-old sham-operated and castrated male Wistar rats were used. One part of the castrated
animals was daily treated with 2.5 mg/kg cyproterone acetate, while the hormone replacement
therapy was performed via an i.m. injection of a dose of 8.0 mg testosterone undecanoate/kg/once
a week. The plasma testosterone level, the activity of HO and myeloperoxidase (MPO) enzymes; the
concentrations of the HO-1, tumor necrosis alpha (TNF-α), and cyclic guanosine monophosphate
(cGMP), as well as the total level of glutathione (GSH + GSSG) were determined from the cardiac
left ventricle. In accordance with the testosterone values, the aging process and castration resulted
in a decrease in antioxidant HO activity, HO-1 and cGMP concentrations and in the level of GSH
+ GSSG, whereas the inflammatory TNF-α and MPO activity significantly increased. Testosterone
therapy was able to restore the physiological values. Our results clearly show that testosterone
replacement therapy increases the antioxidant status and mitigates the inflammatory parameters via
the modulation of the HO system.
Keywords: heme oxygenase; testosterone; inflammation; antioxidant
1. Introduction
Low testosterone level and testosterone deficiency have been associated with the incidence and
progression of chronic diseases, such as metabolic syndrome [1] and cardiovascular diseases (CVDs) [2],
which are the most the common cause of death worldwide. Testosterone may contribute to the
reduction of myocardial infarction and protects the heart against ischemic injury. It has also been
shown that testosterone [3], as well as estrogen, can modulate nitric oxide release, and consequently
influence the vasodilatory mechanisms on blood vessels [4]. While the cardioprotective and
vasodilatory actions have been well documented, the hormonal effects on inflammatory processes and
oxidant/antioxidant homeostasis have not been fully elucidated, and the studied results are controversial.
Chignalia et al. reported that testosterone induces reactive oxygen species (ROS) generation and vascular
smooth muscle cell migration by NADPH oxidase under hypertensive conditions [5]. In addition to the
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effects of NADPH oxidase, androgens also modulate the mitochondrial ROS generation [6]. Beside the
prooxidant effects, numerous studies verify the antioxidant capacity of testosterone in the cardiovascular
system. Zhang et al. demonstrated that testosterone replacement restored the antioxidant capacity
of the heart [7]. As a result of the discrepant outcomes, further investigations of various possible
contributing factors are necessary to study the role of testosterone on oxidant/antioxidant mechanisms.
According to our best knowledge, no reports have been published concerning the relationship
of the heme oxygenase (HO) enzyme system and testosterone level in the myocardium; however,
its cardioprotective effects are significant. HO is a key rate-limiting enzyme in the regulation of cellular
oxidative stress. It catalyzes the degradation of heme and generates biliverdin/bilirubin, free iron and
carbon monoxide (CO), which play a key role in the defense and repair of oxidative stress-induced
damage [8]. The induction of HO-1 is considered to enhance the antioxidant capacity of cells to provide
protection against oxidative stress [9]. While biliverdin and bilirubin are efficient in the scavenging of
ROS, CO contributes significantly to the reduction of pro-inflammatory cytokines [10]. Based on the
antioxidant and anti-inflammatory properties of HO, an examination of the enzyme system might be
a candidate for the understanding of the oxidative status in different testosterone-saturated conditions.
Oxidative stress is involved in age-related dysfunctions and the decline in the testosterone
hormone level and may induce progressive oxidative damages in the cardiovascular system. The aim
of our work is to study the association between the testosterone level and oxidative/inflammatory
processes in male rats subjected to testosterone deprivation (young castrated and aged rats) and
testosterone replacement. To add a significant complexity to the interaction between the testosterone
level and oxidative mechanisms, the HO enzyme activity and concentration as well as the inflammatory
parameters are analysed in the heart.
2. Materials and Methods
2.1. Experimental Protocol
In our study, 10-week-old (young), and 24-month-old (aged) male Wistar rats were used and
housed (Directive 2010/63/EU) at a controlled temperature (20–23 ◦C) on a 12 h light-dark cycle.
Food and water were available ad libitum. All procedures were approved by the Institutional Ethical
Committee and were performed in accordance with the standards of the European Community
guidelines on the care and use of laboratory animals.
Both young and aged rats were randomly divided into the following groups: castrated or control
(sham-operated) animals. During castration surgery, the spermatic cord was tied, the testes were
removed, and the incision was provided by penicillin. The incision was closed, and the rats were
allowed to recover. After a 2-week-recovery period, one part of the young and aged castrated animals
was administrated cyproterone acetate (Bayer AG, Berlin, Germany; 2.5 mg/kg per day, oral treatment)
in order to block the androgen production of the adrenal glands, while the other part of the castrated
rats was treated with testosterone to restore the physiological hormone levels [11]. The testosterone
replacement was performed for 6 weeks via an intramuscular injection of a dose of 8.0 mg/kg testosterone
undecanoate (Nebido, Bayer Schering Pharma AG, Berlin, Germany) once a week dissolved in soybean
oil. The groups that did not receive testosterone replacement were administrated the same volume
of steroid vehicle. The number of the animals per group is detailed in Table 1. Following the
6-week-experimental period, the rats in each group were sacrificed. The serum testosterone and blood
parameters were immediately measured, while the heart left ventricle (LV) samples were excised,
frozen, and kept at −80 ◦C until the biochemical analyses. In our experiment, all efforts were made
to minimize the number of animals as well as the animal’s suffering. The experimental protocol of the
study is shown in Figure 1.
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Table 1. Number of the animals per group (n). CAS = surgical castration, T = testosterone replacement
therapy, Cypr = cyproterone acetate treatment, and SO = sham operation.
Parameters
Young Aging
Fertile CAS CAS + Cypr CAS + T SO CAS CAS + Cypr CAS + T
HO activity 8 8 9 8 9 8 7 9
HO-1 concentration 5 6 4 5 5 5 5 5
GSH + GSSG content 9 9 8 9 8 8 8 9
cGMP level 6 5 4 5 8 6 5 9
MPO activity 8 8 8 8 7 8 7 10
TNF-alpha concentration 8 9 8 7 7 8 8 9
Testosterone level 5 6 4 7 7 6 7 8
GOT level 7 6 4 7 8 7 7 7
GPT level 7 4 4 7 8 4 6 8
Cholesterol level 7 6 4 7 8 7 6 7
Triglyceride level 7 5 4 5 8 6 6 6
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Figure 1. The experimental protocol of the study. CAS = surgical castration, SO = sham operation,
T = testosterone replacement therapy, Cypr = cyproterone acetate treatment, HO = heme oxygenase
enzyme, HO-1 = heme oxygenase-1, GSH + GSSG = reduced glutathione/oxidized glutathione,
MPO = myeloperoxidase enzyme, and cGMP = cyclic guanosine monophosphate.
2.2. Measurement of S rum Testosterone, GOT, GPT, Cholesterol and Triglyceride Levels
The serum levels of total testosterone were analyzed by Immulite 2000XPi (Siemens) chemiluminescent
immunoassay, whereas the glutamic oxaloacetic transaminase (GOT), glutamic-pyruvic transaminase
GPT), cholesterol, and triglyceride levels were measured on the Biolis 24i Premium system (Siemens) at
the end of the 6-week-experimental period. The reactions of GOT and GPT were monitored by measuring
the rate of decrease in absorbance at 340 nm due to the oxidation of NADH into NAD and were expressed
as U/L. The triglyceride and total cholesterol levels were measured at 546 nm and expressed as mmol/L.
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2.3. Measurement of HO Activity
The cardiac LV samples were homogenized in an ice cold buffer [10.0 mM N–2–
hydroxyethylpiperazine–N′–2-ethanesulfonic acid, 0.10 mM ethylenediaminetetraacetic acid disodium
salt dihydrate, 1.0 mM dithiotreitol (DTT), 32.0 mM sucrose, 10.0 µg/mL trypsin inhibitor, 2.0 µg/mL
aprotinin, 10.0 µg/mL leupeptin; pH7.4], centrifuged at 15,000× g for 20 min at 4 ◦C, and the remaining
supernatant was used for the measurements. The reaction mix consisted of a 75 µL sample, 2.0 mM
glucose–6–phosphate, 0.14 U/mL glucose–6–phosphate dehydrogenase, 15.0µM hemin, 120.0µg/mL rat
liver cytosol as a source of biliverdin reductase, and a complex buffer composed of 100.0 mM KH2PO4,
2.0 mM MgCl2 × 6H2O, phenylmethylsulfonyl fluoride, 10.0 µg/mL trypsin inhibitor, 10.0 µg/mL
leupeptin, 2.0 µg/mL aprotinin, and 1.0 mM DTT. Two parallel measurements were done, namely
a blind and a NADPH line. During the NADPH line, in order to initiate the reaction, 100 µL reduced
β-nicotinamide adenine dinucleotide phosphate (β-NADPH) was added into the mixture and it was
incubated for 60 min at 37 ◦C. After 60 min, we applied ice cooling to stop the reaction. For the
blind measurements, we created a mixture in which β-NADPH was replaced with measuring buffer.
NADPH and blind solutions were measured at 465 nm spectrophotometrically; then, the blind values
were subtracted from the NADPH values. The HO activity was represented as the produced amount
of bilirubin (nmol) per hour/mg protein.
2.4. Measurement of Cardiac GSH + GSSG Content
The LV samples were homogenized first in buffer A (0.25 M sucrose, 20 mM Tris, 1 mM DTT) for
60 s on ice, and centrifuged at 15,000× g for 30 min at 4 ◦C. After centrifugation, 1 mL supernatant
was collected and homogenized with 200 µL buffer B (0.25 M sucrose, 20 mM Tris, 1 mM DTT, 0.1 M
CaCl2). After a 30-min incubation, another homogenization was followed at 21,000 g for 30 min at
4 ◦C. The clear cytosolic fraction was used for the enzyme assay. In a 96 wells plate, 40 µL sample or
standard, 20 µL 5,5′ dithio–bis–2–nitrobenzoic acid and 140 µL NADPH were added. This compilation
was incubated for 5 min at 25 ◦C, after which 10 µL glutathione reductase was added to initiate the
reaction. After a 10-min shaking, the 2–nitro–5 thiobenzoic acid formation was monitored at 405 nm.
The GSH levels were expressed as nmol/mg protein.
2.5. Determination of Cardiac HO-1, TNF-Alpha and cGMP Concentrations
LV tissues were homogenized in phosphate buffer (PBS) (pH7.4) for 20 s and placed into the
centrifuge for 20 min at 2500 rpm, at 4 ◦C. The supernatants were collected carefully and used for
ELISA (GenAsia, Shanghai, China) and protein measurements. According to the manufacturer’s
instruction, the LV concentrations were determined at 450 nm. The HO-1 levels were expressed as
ng/mg protein, the TNF-α values were defined as pg/mg protein, while the cGMP concentration was
given as pmol/mg protein.
2.6. Measurement of MPO Activity
The rat LV tissues were homogenized twice for 10 s in a dissolvent containing PBS and 0.5%
hexadecyltrimethylammoniumbromide (HETAB). The samples were frozen and melted four times,
and then centrifuged at 10,000× g for 15 min at 4 ◦C. In a 96 wells plate, 12 µL standard or sample was
mixed with 280 µL o-dianisidine dihydrochloride, and the reaction was initiated with 20 µL hydrogen
peroxide. The mixture was shaken for 30 s, after which the activity of MPO was detected at 490 nm
spectrophotometrically. The values were expressed as µU/mg protein.
Antioxidants 2019, 8, 288 5 of 12
2.7. Protein Determination
Using a commercial protein assay kit (Bio-Rad Labs), aliquots (20 µL) of the diluted samples
were mixed with 980 µL of distilled water, with 200 µL Bradford reagent added to each sample. After
mixing and following a 10 min incubation, the samples were assayed spectrophotometrically at 595 nm.
The protein level was expressed as mg protein/mL.
2.8. Statistical Analysis
The results are expressed as the means ± S.E.M. The differences between groups were calculated
using a one-way ANOVA followed by Tukey post-testing, and p ≤ 0.05 was considered as significant.
3. Results
3.1. Changes in Serum Testosterone
At the end of the experimental period, the serum testosterone levels were measured in both young
and aged animals. As expected, the hormone level was significantly reduced by the aging process,
and it was undetectable in the castrated (CAS and CAS + Cypr) groups. Treatment with testosterone
undecanoate resulted in the restoration of the androgen level in young animals, and caused a further
enhancement in the case of aged animals. The data are presented in Table 2.
Table 2. Changes in the serum levels of testosterone (expressed as: ng/dL), glutamic oxaloacetic
transaminase (GOT: expressed as U/L), glutamic-pyruvic transaminase (GPT: expressed as (U/L),
cholesterol (expressed as mmol/L), and triglyceride (expressed as mmol/L). The results are shown
as the means ± S.E.M. n = 4–10. * p < 0.05: Statistical significance relative to the Young/SO
fertile group, # p < 0.05: Statistical significance between age-matched CAS and CAS + T groups,
CAS = surgical castration, T = testosterone replacement therapy, Cypr = cyproterone acetate treatment,
and SO = sham operation.
Young Aging
Fertile CAS CSA + Cypr CAS + T SO CAS CAS + Cypr CAS + T
Testosterone (ng/dl) 237.40 ± 36.58 0 ± 0 * 0 ± 0 * 149.86 ± 21.19 # 95.90 ± 12.26 * 0 ± 0 * 0 ± 0 * 364.50 ± 50.19 *,#
GOT (U/l) 94.57 ± 3.02 106.67 ± 11.85 142.50 ± 23.50 105.14 ± 3.91 184.75 ± 18.72 * 163.86 ± 6.11 * 163.00 ± 10.64 * 145.29 ± 13.03
GPT (U/l) 56.00 ± 1.60 5.00 ± 1.22 77.00 ± 6.23 59.57 ± 1.85 94.00 ± 10.10 * 88.25 ± 3.66 * 90.67 ± 6.38 * 79.13 ± 5.11
Cholesterol (mmol/l) 2.20 ± 0.13 2.78 ± 0.13 3.09 ± 0.12 2.29 ± 0.08 3.86 ± 0.44 4.65 ± 0.63 * 4.81 ± 0.86 * 4.46 ± 0.51 *
Triglyceride (mmol/l) 0.92 ± 0.13 1.01 ± 0.06 2.84 ± 0.39 * 1.28 ± 0.13 1.62 ± 0.31 1.69 ± 0.27 1.75 ± 0.30 1.33 ± 0.15
3.2. Measurement of Cardiac HO Activity and HO-1 Concentration
The efficacy of the aging process, surgical castration, and hormone replacement therapy was
examined on the antioxidant HO enzyme system. As shown in Figure 2A, a significant decrease of the
cardiac HO activity was observed in both aged animals and castrated rats. However, no differences
existed between the CAS and CAS + Cypr groups. Supplements of testosterone for 6 weeks enhanced
the HO activity, which was statistically similar in both young and aging CAS + T groups.
In agreement with the HO activity results, the testosterone deficiency in aged and castrated
animals resulted in a significant reduction in the HO-1 concentration compared with the young/fertile
SO rats. The reduced HO-1 values were compensated by testosterone therapy in both CAS + T groups.
The data are presented in Figure 2B.
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Figure 2. (A) The effects of aging, surgical castration, and testosterone replacement therapy on the
cardiac HO activity (HO; expressed as nmol bilirubin/h/mg protein). The results are shown as the means
± S.E.M. n = 7–9. (B) The effects of aging, surgical castration, and testosterone replacement therapy on
the cardiac HO-1 concentration (HO-1; expressed as ng/mg protein). The results are shown as the means
± S.E.M. n = 4–7. * p < 0.05: Statistical significance relative to the Young/SO fertile group, # p < 0.05:
Statistical significance between age-matched CAS and CAS + T groups, CAS = surgical castration,
T = testosterone replacement therapy, Cypr = cyproterone acetate treatment, and SO = sham operation.
3.3. Determination of Cardiac GSH + GSSG Content
As shown in Figure 3A, the fertile SO rats exhibited the highest GSH + GSSG value, whereas
a significant decrease was found in testostero e-deficient (aging and CAS) animals. As a result of
the 6-week-testosterone treatment, a significant improvement in the cardiac antioxidant status was
detected in both young and aged rats.
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Figure 3. (A) The effects of aging, surgical castration, and testosterone replacement therapy on the
ratio of the reduced/oxidized glutathione content (GSH + GSSG; expressed as nmol/mg protein).
The results are shown as the means ± S.E.M. n = 8–9. (B) The effects of aging, surgical castration,
and testosterone replacement therapy on the cardiac cyclic guanosine monophosphate level (cGMP;
expressed as nmol/mg protein). The results are shown as the means ± S.E.M. n = 8–9. * p < 0.05:
Statistical significance relative to the Young/SO fertile group, # p < 0.05: Statistical significance between
age-matched CAS and CAS + T groups, CAS = surgical castration, T = testosterone replacement therapy,
Cypr = cyproterone acetate treatment, and SO = sham operation.
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3.4. Evaluation of Cardiac cGMP Level
The cardiac cGMP level reached the highest value in the Young/fertile SO rats, while testosterone
deprivation resulted in a significant reduction in the CAS and CAS +Cypr groups. Similarly, in the aging
groups with a lower testosterone level, the cardiac cGMP levels were significantly lower compared to
the young/fertile SO rats. Exogenous testosterone replacement therapy was efficient in both young and
aged animals. The data are presented in Figure 3B.
3.5. Cardiac MPO Activity
Figure 4A presents the MPO values measured at the end of the experimental period. As expected,
testosterone deficiency caused by aging or surgical castration resulted in a significant increase in the
inflammatory processes, as shown by the elevation of the MPO activity. However, testosterone-treated
rats possessed lower values compared to the untreated counterparts.
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Figure 4. (A) The effects of aging, surgical castration, and testosterone replacement therapy on the
cardiac myeloperoxidase enzyme activity (MPO; expressed as uU/mg protein). The results are shown as
the means ± S.E.M. n = 7–10. (B) The effects of aging, surgical castration, and testosterone replacement
therapy on the cardiac tumor necrosis factor-alpha concentration (TNF-α; expressed as pg/mg protein).
The results are shown as the means ± S.E.M. n = 7–9 * p < 0.05: Statistical significance relative to the
Young/SO fertile group, # p < 0.05: Statistical significance between age-matched CAS and CAS + T
groups, CAS = surgical castration, T = testosterone replacement therapy, Cypr = cyproterone acetate
treatment, and SO = sham operation.
3.6. Cardiac TNF-α Concentration
Similar to the MPO activity values, the TNF-α concentrations were significantly increased with
regards to the aged and castrated animals. 6 weeks of testosterone therapy was able to mitigate these
elevated values in both the young and aging CAS + T groups. The data are presented in Figure 4B.
3.7. Serum GOT, GPT, Cholesterol, and Triglyceride Concentrations
A similar result was observed in the case of the GOT and GPT concentrations when the aging
status resulted in a significant increase in the GOT and GPT values compared to the young/fertile
SO rats.
The serum cholesterol and triglyceride concentrations were enhanced in castrated and aged rats,
and the highest values were observed in the case of the CAS + Cypr groups. We can summarize
that hormone replacement therapy was able to ameliorate the metabolic parameters, except for the
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cholesterol values of aged rats where testosterone treatment did not mitigate the castration-induced
adverse changes.
4. Discussion
In the present study, the relationship between the testosterone level, oxidant/antioxidant
homeostasis, as well as the inflammatory parameters has been determined. Our results show that
testosterone deprivation caused by the aging process or surgical castration deteriorated the antioxidant
status of LV and resulted in higher levels of inflammatory parameters via the modulation of the HO
system. Hormone replacement therapy was observed to prevent oxidative damage, which was effective
in both young and aged rats.
A number of studies support the view that endogenous sex hormones possess an important
role in the cardiovascular system and in the maintenance of the normal lipid profile [12]. Similar
to estrogen deficiency [13,14], a low testosterone level is an independent cardiovascular risk factor
and produces adverse effects on cardiac function due to the presence of androgen receptors in the
myocardium [15]. Based on the antioxidative effects of sex hormones, a decline in the testosterone
level causes homeostatic shifts toward the oxidative stress [16]. Our current results show that the
testosterone level could be aligned with the antioxidant/oxidant state. We found an age-related
decrease in the testosterone level of aged animals (~63%), while testosterone concentrations in castrated
animals dropped to zero. Hormone replacement therapy restored testosterone levels in young animals,
and exceeded the physiological value in the aged group. To provide evidence that testosterone absence
contributes to the deterioration of antioxidant defense mechanisms, the role of the cardiac HO enzyme
system has been analysed. HO enzymes occur in many mammalian tissues, and possess antioxidant
and anti-inflammatory properties via the release of its by-products (biliverdin/bilirubin, CO, and free
iron). The relationship of the HO system and the testosterone level in the myocardium has not been
previously investigated; however, the effects of estrogen, the other sex hormone, on the HO system has
been widely distributed in the cardiovascular system [17–20]. In our previous study, we verified that
estrogen deprivation related to the aging process or to pharmacologically/surgically-induced hormone
deficiency resulted in a significant decrease of the cardiac HO activity and expression [13]. The onset of
cardiovascular complications coincided with the reduced HO activity and expression, as well as with
a linear increase in the MPO enzyme activity and in the concentrations of the TNF-α pro-inflammatory
cytokine. Demirbag et al. associated the sex hormones with the total antioxidant capacity and found
a strong correlation between the antioxidants, testosterone, and estrogen hormones [21]. Beside sex
hormones, the aging process with its multifactorial properties influences the oxidant/antioxidant
homeostasis. Oxidative stress and the reduction of antioxidant mechanisms are general in aged animals,
promoting the development of cardiovascular pathological processes [22]. In agreement with previous
observations, our results clearly show that the aging process contributed to the deterioration of the
antioxidant state via the diminishment of the HO system. Surgical castration induced a significant
decrease in the cardiac HO enzyme activity and HO-1 concentration in both young and aged animals,
while cyproterone acetate-treated rats possessed the lowest HO values as a result of the absolute block
of androgen production. Similar to estrogen replacement therapy [23], we observed a protective role of
testosterone administration against oxidative damages. Exogenous testosterone-induced amelioration
was effective in both young and aged animals. It has been proven that endogenous sex hormones
protect the cells form oxidative damage; however, conflicting results have been observed in connection
with the potential antioxidant role of exogenous testosterone. Klapcinska et al. found that castration
negatively influenced the antioxidant status of the rat heart, which was further decreased due to
androgen replacement therapy [24]. In a similar experimental design, Zhang et al. investigated the
regulation of the cardiac redox state. They found that testosterone deficiency induced oxidative stress,
while exogenous testosterone ameliorated superoxide dismutase and glutathione peroxidase enzyme
activities in the cardiomyocytes [7]. Under oxidative stress, various antioxidant defense systems
contribute to scavenging ROS; however, the activities of these systems depend mostly on the duration
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of exposure and the intensity of the oxidative stress. While the defense pathways could be adversely
affected, the HO system, by its antioxidant, anti-inflammatory, anti-proliferative and vasodilative
properties, clearly proved the beneficial effect of testosterone-mediated cardioprotective processes.
Beside animal studies, the testosterone level in humans has been also examined and associated
with their cardiovascular health. Hormonal decline increases the risk of myocardial infarction [25],
coronary heart disease [26] and promotes further comorbidities [27]. Mancini et al. reported that
testosterone replacement restored the antioxidant capacity to normal values, suggesting the protective
role of the hormone [28]. In order to verify our hypothesis about the protective role of testosterone
replacement therapy, the cardiac GSH/GSSG content has been also measured. Our study indicates
that the aging process and testosterone deficiency resulted in a significant decrease in the level of
GSH/GSSG as compared to fertile animals; however, exogenous hormone administration improved
these reduced values.
In line with the antioxidant capacity, the inflammatory parameters were also changed in various
testosterone-saturated conditions. It has been well documented that the incidence and progression
of chronic diseases show a strong correlation with the high levels of inflammatory markers [29].
Testosterone deprivation-induced inflammatory processes correlate with the increase of the adverse
metabolic parameters. Inflammatory and metabolic markers alone or together promote the incidence
and progression of various pathological cardiovascular processes [30]. Haring et al. verified that the
plasma level of sex steroids in men shows a negative correlation with inflammatory parameters [31].
Whereas inflammation is elevated in hypogonadal men, testosterone therapy is able to attenuate the
pathological values. In accordance with the human results, we have also proved that exogenous
testosterone treatment mitigated the MPO enzyme activity and the concentration of TNF-α, which were
increased in testosterone-deficient groups. A growing body of evidences have demonstrated that HO-1
and its metabolites play a key role in the attenuation of pro-inflammatory cytokines. HO-1 reduces the
production of TNF-α, interleukin (IL)-1β, and IL-6 vice versa, while the level of anti-inflammatory
cytokines are elevated due to the protective effects of HO [30]. Kapturczak et al. verified in HO-1
knockout mice that the absence of HO-1 correlated with the inflammatory state [32]. Our findings are
consistent with the anti-inflammatory role of HO-1. The cardiac HO activity and HO-1 concentration
were reduced in line with elevated TNF-α values in aged or castrated animals, whereas hormone
replacement therapy improved the antioxidant/inflammatory balance. We can summarize that
a similar association could be observed between the HO and MPO activity and in the interplay
of HO and TNF-α. Sexual hormones mediate their effects via binding to their receptors, and they
activate DNA-binding or non-DNA-binding-dependent actions [33]. Among steroid hormones,
testosterone is a potential inductor of HO enzymes and causes antioxidant, anti-inflammatory,
and anti-proliferative effects via releasing CO and bilirubin biological products. It has been well
documented that the effects of CO resemble those of NO due to their common signaling pathways.
Androgen receptor-bound testosterone triggers the ERK1/2-MAPK cascade to regulate the nitric oxide
synthase (NOS)/NO pathway and mediate its effect affected by cGMP [34]. However, the amount
of CO has not been measured in this study; our results related to the cGMP content support this
interaction. The production of the anti-inflammatory compounds biliverdin/bilirubin and CO play
a major role in counteracting inflammatory reactions. Similar to the nitric oxide (NO)-cGMP signalling
mechanism, CO-regulated cGMP production has a beneficial role against vascular inflammation and
in many cardiovascular complications [35]. Rizzo et al. reported that reduced NO-cGMP signalling
is a trigger of vascular inflammation and insulin resistance [36]. Consistent with the data of the HO
activity, HO-1 concentration as well as the inflammatory markers, our findings present reduced cGMP
values in the lack of testosterone. The protective role of exogenous therapy against inflammation
has also been reflected in the elevated level of cGMP. Beside the oxidative and inflammatory effects,
metabolic parameters also increase the risk of cardiovascular diseases. Changes in the lipid profile are
correlated with the testosterone level. In agreement with Rouver et al. [37], we demonstrated that the
concentrations of cholesterol, triglyceride, and GOT levels were increased as a result of testosterone
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deficiency, whereas exogenous hormone therapy ameliorated the adverse values. Advancing age
increased the lipid parameters in themselves, and they were further elevated in the aged-castrated
animals. Similar to the antioxidant and anti-inflammatory properties, the metabolic parameters were
also improved as a result of testosterone administration.
In summary, we can conclude that the HO system is involved in testosterone-mediated mechanisms
in both young and aged animals. In addition to the effects of the endogenous sex hormone, exogenous
hormone therapy promotes antioxidants and anti-inflammatory processes via the enhancement of
the HO enzymes. Although aging processes are associated with oxidative damages, hormonal
treatment restores the adverse antioxidant/inflammatory balance in the heart, which may improve the
cardiovascular health of testosterone-deficient patients.
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